Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 3c; Reports Cash and Cash Equivalents of $166.7M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Far-left party wins Berlin election, pledging to nationalise housing
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
November 5, 2021 7:30 AM EDTFirst Patient Dosed in SELECT-AML-1 Trial of Tamibarotene and in Dose Confirmation Study of SY-2101 in APL
Presented Phase 1 Data of SY-5609 at ESMO, Demonstrating Clinical Activity at Tolerable Doses and Supporting Development in Three Combination Regimens
Expanded Leadership Team with Key Appointments
Management to Host Conference Call at 8:30 a.m. ET Today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today... More
